Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

“…Among them, derivative <b>A11</b> had the most potent antiproliferative activity against A549 lung cancer cells (IC₅₀ = 0.009 μM) and was approximately 10-fold more potent than CuB, while the cytotoxicity of <b>A11</b> toward normal L02 cells was about 10-fold less potent, indicating a much wider therapeutic window than CuB. …”

Baseline level biochemical and circulating biomarkers in study subjects. by Jaskiran Kaur (160829)

Change in serum levels of vitamin D and angiogenic marker at 16 weeks follow-up. by Jaskiran Kaur (160829)

Osr1 heterozygous mice experienced decreased bile acid synthesis in the liver. by Ernest C. Lynch (12769954)

“…(D) Osr1 heterozygous male mice had significantly decreased expression of <i>Cyp7a1</i>, <i>Cyp27a1</i>, <i>Ehhadh</i>, <i>Cyp4a10</i> and <i>Cyp4a14</i> compared to WT male mice. …”

Nectin-1 staining is decreased in HSV1-infected keratinocytes, but enhanced as a collar in surrounding uninfected cells. by Hafsa Rana (8201886)

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

Image10_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

COVID-19 incidence increases over time with a decreased importance of genetic COVID-19 susceptibility. by C. A. Robert Warmerdam (12568808)

Supplementary Material for: MicroRNA-125a Correlates with Decreased Psoriasis Severity and Inflammation and Represses Keratinocyte Proliferation by Su F. (4127968)

Fig 10 - by Mohammad R. Nikmaneshi (16185668)

Loss of <i>SLC4A11</i> expression in hCEnC leads to decreased cell barrier function. by Doug D. Chung (3611387)

Fig 10 - by Arun Prakash (3256941)

Experimental outline. by Melissa A. MacIver (12850566)

Subjects:

Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Decrease in circulating iNKT cell activation during regadenoson (RA) infusion into patients with COVID-19. by Joseph Rabin (7399436)

Subjects:

Number of SBs with <i>s</i> = 10 cited by patents as a function of number of patent citations n(pc), citation windows 5 and 10 year. by Anthony F. J. van Raan (7517696)

Simulation of parasite motion with a decreased flagellum stiffness of . by Florian A. Overberg (21402904)